CMS Open Payments · Program Year 2024
IlluminOss Medical, Inc.
IlluminOss Medical, Inc. reported $293,677.78 across General Payments, Research, and Ownership to 469 physicians and teaching hospitals across 486 transactions.
- $293.7K Above-median payer
- All-tracks total
- 486 Above-median volume
- Transactions
- 469 Above-median reach
- Recipients
- +$20.6K
- General Payments vs PY2023
IlluminOss Medical, Inc. reported $293,677.78 across all CMS Open Payments tracks (General + Research + Ownership) to 469 physicians and teaching hospitals in Program Year 2024 - ranking #894 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $168,851.78, averaging $626.18 per recipient.
How IlluminOss Medical, Inc.'s $293.7K all-tracks total breaks down
IlluminOss Medical, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
13/100
Transaction volume
F
14/100
Physician reach
F
14/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer illuminoss-medical-inc IlluminOss Medical, Inc.
$293.7K · #894/1,925 · 0.0% industry · PY2024
- TOT $293.7K
- RANK #894
- SHARE 0.0%
- TXN 486
- RCP 469
- CAT 5
- GEN $168.9K
- ΔGEN +$20.6K
- TOP1 17.6%
- PY 2024
Volume peers
Nearest volume peer: Verity Pharmaceuticals Inc. ($293.4K)
IlluminOss Medical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
IlluminOss Medical, Inc.'s CMS-reported General Payments increased by $20.6K (+13.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ILLUMINOSS MEDICAL, INC.PY2023: ILLUMINOSS MEDICAL, INC.PY2024: IlluminOss Medical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $148,286.15
- PY2024
- $168,851.78
What the Data Shows for IlluminOss Medical, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For IlluminOss Medical, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $57.6K, accounting for 34.1% of this company's General Payments and 22 transactions.
General Payment Breakdown by Type
Across 5 types of general payments, IlluminOss Medical, Inc.'s largest category was "Honoraria" at $57.6K - 34.1% of General Payments.
IlluminOss Medical, Inc. reports 5 general-payment categories - the top three are Honoraria (34.1%), Consulting Fee (32.2%), and Education (16.6%). The remaining 2 categories make up 17.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How IlluminOss Medical, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $57.6K | 22 | 34.1% |
| Consulting Fee | $54.3K | 75 | 32.2% |
| Education | $28.0K | 7 | 16.6% |
| Food and Beverage | $23.0K | 360 | 13.6% |
| Travel and Lodging | $5.9K | 5 | 3.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $69,890.81 (41.4%) of $168,851.78 in this company's General Payments records across 294 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for IlluminOss Medical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
William Hartman Harvin
$29,681.60 across 15 reported transactions
- 2
Kyle Mobley
$13,392.38 across 4 reported transactions
- 3
Christopher Born
$10,790.00 across 3 reported transactions
- 4
James Daniel Hlavacek
$8,125.47 across 7 reported transactions
- 5
Brooke M. Crawford
$7,901.36 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
IlluminOss Medical, Inc. ranks #894 of 1,925 by total payments (top 46% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,240 of 1,838 by HHI (bottom 33% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Getinge USA Sales, LLC : $462.9K total payments, HHI 589
- Henry Schein One, LLC : $39.9K total payments, HHI 589
- Nsk America Corporation : $1.2K total payments, HHI 588
- Merck KGaA : $285.7K total payments, HHI 587
- CONMED Corporation : $945.9K total payments, HHI 586
- Accuray Incorporated : $113.0K total payments, HHI 584
- IlluminOss Medical, Inc. (this company) : $168.9K total payments, HHI 583
- Medacta USA, Inc. : $8.4M total payments, HHI 583
- Kub Technologies Inc. : $14.7K total payments, HHI 583
- Acorda Therapeutics, Inc : $192.5K total payments, HHI 580
- Bayer Healthcare LLC : $279.6K total payments, HHI 578
- Nexxt Spine LLC : $292.8K total payments, HHI 576
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as IlluminOss Medical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about IlluminOss Medical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with IlluminOss Medical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Nexxt Spine LLC
Evoke Pharma, Inc.
Exo Imaging, Inc.
Episurf Medical, Inc.
Intra-Sana Laboratories
Put this to use
IlluminOss Medical, Inc. ranks #894 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just IlluminOss Medical, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.